核苷类抗病毒前药的研究进展  

Strategy in the study of nucleoside antiviral prodrugs

作　　者：冷玲颖[1] 蔡志强[1] 孙铁民[1] 

机构地区：[1]沈阳药科大学制药工程学院,辽宁沈阳110016

出　　处：《中国药物化学杂志》2008年第4期310-316,共7页Chinese Journal of Medicinal Chemistry

摘　　要：一些核苷类抗病毒药物口服给药后,水溶性和口服生物利用度都很差,对这些药物进行修饰,制成其前药的形式,来克服这些不足是非常重要的。该文阐述了近年来核苷类抗病毒前药的设计方法,列举了一些核苷类抗病毒前药并讨论了这些化合物的活性机理。Some of the nucleoside antiviral drugs suffer from low aqueous solubility and low bioavailability following oral administration. New nucleoside analogues, which were developed to overcome this problem, are very important. In this review, we intend to highlight the designing ways of antiviral nucleoside prodrugs which were developed in recent years with examples. And their action mechanisms are also discussed.

关 键 词：核苷类抗病毒前药 伐昔洛韦 法昔洛韦 缬更昔洛韦 

分 类 号：R978.7[医药卫生—药品]